Pharmaceuticals in Poland
Published: November 2012 · Publisher: MarketLine
Pharmaceuticals in Poland industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016).
- Description
- Table of Contents
- Ask a Question
Introduction
Pharmaceuticals in Poland industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Poland pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
*The Polish pharmaceuticals market had total revenues of $8.1 billion in 2011, representing a compound annual growth rate (CAGR) of 5.6% between 2007 and 2011.
*0
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 2.6% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $9.2 billion by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Poland
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Poland
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Poland pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Poland economy
Key Questions Answered
What was the size of the Poland pharmaceuticals market by value in 2011?
What will be the size of the Poland pharmaceuticals market in 2016?
What factors are affecting the strength of competition in the Poland pharmaceuticals market?
How has the market performed over the last five years?
Pharmaceuticals in Poland industry profile provides top-line qualitative and quantitative summary information including: market size (value 2007-11, and forecast to 2016). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the Poland pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Highlights
*The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
*The Polish pharmaceuticals market had total revenues of $8.1 billion in 2011, representing a compound annual growth rate (CAGR) of 5.6% between 2007 and 2011.
*0
*The performance of the market is forecast to decelerate, with an anticipated CAGR of 2.6% for the five-year period 2011 - 2016, which is expected to drive the market to a value of $9.2 billion by the end of 2016.
Features
Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Poland
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Poland
Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Poland pharmaceuticals market with five year forecasts
Macroeconomic indicators provide insight into general trends within the Poland economy
Key Questions Answered
What was the size of the Poland pharmaceuticals market by value in 2011?
What will be the size of the Poland pharmaceuticals market in 2016?
What factors are affecting the strength of competition in the Poland pharmaceuticals market?
How has the market performed over the last five years?
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
TABLE OF CONTENTS
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
GlaxoSmithKline Plc 20
Sanofi 24
Novartis AG 27
Polpharma SA 30
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34
LIST OF TABLES
Table 1: Poland pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Poland pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Poland pharmaceuticals market share: % share, by value, 2011 10
Table 4: Poland pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: GlaxoSmithKline Plc: key facts 20
Table 6: GlaxoSmithKline Plc: key financials ($) 21
Table 7: GlaxoSmithKline Plc: key financials (L) 22
Table 8: GlaxoSmithKline Plc: key financial ratios 22
Table 9: Sanofi: key facts 24
Table 10: Sanofi: key financials ($) 25
Table 11: Sanofi: key financials (€) 25
Table 12: Sanofi: key financial ratios 25
Table 13: Novartis AG: key facts 27
Table 14: Novartis AG: key financials ($) 28
Table 15: Novartis AG: key financial ratios 28
Table 16: Polpharma SA: key facts 30
Table 17: Poland size of population (million), 2007–11 31
Table 18: Poland gdp (constant 2000 prices, $ billion), 2007–11 31
Table 19: Poland gdp (current prices, $ billion), 2007–11 31
Table 20: Poland inflation, 2007–11 32
Table 21: Poland consumer price index (absolute), 2007–11 32
Table 22: Poland exchange rate, 2007–11 32
LIST OF FIGURES
Figure 1: Poland pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Poland pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Poland pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Poland pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Poland, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Poland, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Poland, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Poland, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Poland, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Poland, 2011 19
Figure 11: GlaxoSmithKline Plc: revenues & profitability 22
Figure 12: GlaxoSmithKline Plc: assets & liabilities 23
Figure 13: Sanofi: revenues & profitability 26
Figure 14: Sanofi: assets & liabilities 26
Figure 15: Novartis AG: revenues & profitability 29
Figure 16: Novartis AG: assets & liabilities 29
Executive Summary 2
Market value 2
Market value forecast 2
Geography segmentation 2
Market share 2
Market rivalry 2
Market Overview 7
Market definition 7
Market analysis 7
Market Data 8
Market value 8
Market Segmentation 9
Geography segmentation 9
Market share 10
Market Outlook 11
Market value forecast 11
Five Forces Analysis 12
Summary 12
Buyer power 13
Supplier power 15
New entrants 16
Threat of substitutes 18
Degree of rivalry 19
Leading Companies 20
GlaxoSmithKline Plc 20
Sanofi 24
Novartis AG 27
Polpharma SA 30
Macroeconomic Indicators 31
Country Data 31
Appendix 33
Methodology 33
Industry associations 34
Related research 34
LIST OF TABLES
Table 1: Poland pharmaceuticals market value: $ billion, 2007–11 8
Table 2: Poland pharmaceuticals market geography segmentation: $ billion, 2011 9
Table 3: Poland pharmaceuticals market share: % share, by value, 2011 10
Table 4: Poland pharmaceuticals market value forecast: $ billion, 2011–16 11
Table 5: GlaxoSmithKline Plc: key facts 20
Table 6: GlaxoSmithKline Plc: key financials ($) 21
Table 7: GlaxoSmithKline Plc: key financials (L) 22
Table 8: GlaxoSmithKline Plc: key financial ratios 22
Table 9: Sanofi: key facts 24
Table 10: Sanofi: key financials ($) 25
Table 11: Sanofi: key financials (€) 25
Table 12: Sanofi: key financial ratios 25
Table 13: Novartis AG: key facts 27
Table 14: Novartis AG: key financials ($) 28
Table 15: Novartis AG: key financial ratios 28
Table 16: Polpharma SA: key facts 30
Table 17: Poland size of population (million), 2007–11 31
Table 18: Poland gdp (constant 2000 prices, $ billion), 2007–11 31
Table 19: Poland gdp (current prices, $ billion), 2007–11 31
Table 20: Poland inflation, 2007–11 32
Table 21: Poland consumer price index (absolute), 2007–11 32
Table 22: Poland exchange rate, 2007–11 32
LIST OF FIGURES
Figure 1: Poland pharmaceuticals market value: $ billion, 2007–11 8
Figure 2: Poland pharmaceuticals market geography segmentation: % share, by value, 2011 9
Figure 3: Poland pharmaceuticals market share: % share, by value, 2011 10
Figure 4: Poland pharmaceuticals market value forecast: $ billion, 2011–16 11
Figure 5: Forces driving competition in the pharmaceuticals market in Poland, 2011 12
Figure 6: Drivers of buyer power in the pharmaceuticals market in Poland, 2011 13
Figure 7: Drivers of supplier power in the pharmaceuticals market in Poland, 2011 15
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Poland, 2011 16
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Poland, 2011 18
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Poland, 2011 19
Figure 11: GlaxoSmithKline Plc: revenues & profitability 22
Figure 12: GlaxoSmithKline Plc: assets & liabilities 23
Figure 13: Sanofi: revenues & profitability 26
Figure 14: Sanofi: assets & liabilities 26
Figure 15: Novartis AG: revenues & profitability 29
Figure 16: Novartis AG: assets & liabilities 29
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.